-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 PViva//JSw1il+mw2SNYPMjeLgNdlKgCsQmtXZrMUO57JSWdsHNLG2lc4lCNWIkd
 zi+A/8Si7rc5vT4bLvKb4A==

<SEC-DOCUMENT>0001181431-04-047993.txt : 20041019
<SEC-HEADER>0001181431-04-047993.hdr.sgml : 20041019
<ACCEPTANCE-DATETIME>20041019130553
ACCESSION NUMBER:		0001181431-04-047993
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20041018
ITEM INFORMATION:		Entry into a Material Definitive Agreement
FILED AS OF DATE:		20041019
DATE AS OF CHANGE:		20041019

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OXIS INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000109657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				941620407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-08092
		FILM NUMBER:		041084787

	BUSINESS ADDRESS:	
		STREET 1:		6040 N CUTTER CIRCLE STE 317
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97217
		BUSINESS PHONE:		5032833911

	MAIL ADDRESS:	
		STREET 1:		6040 N CUTTER CIRCLE STE 317
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97217

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DDI PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DIAGNOSTIC DATA INC /DE/
		DATE OF NAME CHANGE:	19850312
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rrd55135.htm
<DESCRIPTION>8-K, DIRECTOR OPTIONS
<TEXT>



<HTML>


<HEAD>








<TITLE>UNITED STATES</TITLE>


</HEAD>


<BODY LINK="#0000ff">





<B><FONT SIZE=4><P ALIGN="CENTER">UNITED STATES</P>


<P ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION</P>


</B></FONT><FONT SIZE=2><P ALIGN="CENTER">Washington, D.C. 20549</P>


<P ALIGN="CENTER"></P>


<P ALIGN="CENTER">&nbsp;</P>


<P ALIGN="CENTER">&nbsp;</P>


</FONT><B><FONT SIZE=5><P ALIGN="CENTER">FORM 8-K</P>


</FONT><FONT SIZE=4><P ALIGN="CENTER"></P>


</B></FONT><P ALIGN="CENTER">Current Report</P>


<P ALIGN="CENTER"></P>


<P ALIGN="CENTER">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</P>


<P ALIGN="CENTER"></P>


<P ALIGN="CENTER">Date of Report (Date of earliest event reported): October 12, 2004</P>


<P ALIGN="CENTER"></P>


<B><FONT SIZE=5><P ALIGN="CENTER">OXIS INTERNATIONAL, INC.</P>


</B></FONT><I><P ALIGN="CENTER">(Exact name of registrant as specified in its charter)</P>


</I><P ALIGN="CENTER"></P>


<P ALIGN="CENTER">&nbsp;</P>


<B><P ALIGN="CENTER">Delaware</P>


</B><I><P ALIGN="CENTER">(State or other jurisdiction of incorporation)</P>


</I><P ALIGN="CENTER"></P>


<P ALIGN="CENTER">&nbsp;</P>


<TABLE CELLSPACING=0 BORDER=0 CELLPADDING=7 WIDTH=590>


<TR><TD WIDTH="50%" VALIGN="TOP">


<B><P ALIGN="CENTER">0-8092</B></TD>


<TD WIDTH="50%" VALIGN="TOP">


<B><P ALIGN="CENTER">94-1620407</B></TD>


</TR>


<TR><TD WIDTH="50%" VALIGN="TOP">


<I><P ALIGN="CENTER">(Commission File Number)</I></TD>


<TD WIDTH="50%" VALIGN="TOP">


<I><P ALIGN="CENTER">(I.R.S. employer identification No.)</I></TD>


</TR>


</TABLE>








<P>&nbsp;</P>


<P>&nbsp;</P>


<P ALIGN="CENTER">6040 N. Cutter Circle, Suite 317 </P>


<P ALIGN="CENTER">Portland, OR 97217-3935 </P>


<I><P ALIGN="CENTER">(Address of Principal Executive Office, Including Zip Code) </P>


</I><P ALIGN="CENTER"></P>


<P ALIGN="CENTER">&nbsp;</P>


<P ALIGN="CENTER">&nbsp;</P>


<B><P ALIGN="CENTER">(503) 283-3911</P>


</B><I><P ALIGN="CENTER">(Registrant's telephone number, including area code)</P>


</I><P ALIGN="CENTER"></P>


<B><P ALIGN="CENTER">&nbsp;</P>


<P ALIGN="CENTER">&nbsp;</P>


<P ALIGN="CENTER">Not applicable </P>


</B><I><P ALIGN="CENTER">(Former name or former address, if changed since last report) </P>


</I>


<B><P>Item 1.01.  Material Definitive Agreement</P>


</B><P>On October&nbsp;12, 2004, OXIS International, Inc. (the &quot;Company&quot;) granted to each current member of its Board of Directors an option to purchase shares of Common Stock of the Company.  Directors S. Colin Neill and Gosse B. Bruinsma, M.D. each were granted a nonqualified option to purchase 100,000 shares of the Company's Common Stock under its 2003 Stock Incentive Plan (the &quot;Plan&quot;).  Directors Steven H. Ferris, M.D., Timothy C. Rodell, M.D., Gerard J. Vlak, Ph.D. and Marvin S. Hausman, M.D. were each granted a nonqualified option to purchase 50,000 shares of the Company's Common Stock under the Plan.</P>


<P>The general terms of each option are identical and are consistent with the Company's standard form of stock option agreement under the Plan.  Each option has an exercise price of $0.59 per share, the closing price of the Company's Common Stock on October 11, 2004 (as such closing price is quoted on the over-the-counter market (Bulletin Board)).  Subject to continued Service (as defined in the Plan) to the Company by the optionee, and certain other limitations, the option rights may be exercised, in whole or in part, in accordance with the following schedule:  (a) 50% of the shares subject to the option, or any part thereof, may be exercised at any time or times, from and including October 12, 2004 to and including October 11, 2014; (b) an additional 25% of the shares subject to the option, or any part thereof, may be exercised at any time or times, from and including October&nbsp;12, 2005 to and including October 11, 2014; and (c) an additional 25% of the shares subject to the option, or any part thereof,
 may be exercised at any time or times, from and including October 12, 2006 to and including October 11, 2014.  Under the terms of each of the options granted to directors on October&nbsp;12, 2004, upon termination of the optionee's Service to the Company, the optionee would have one year to exercise the portion of the option that had become vested as a result of the optionee's Service to the Company.</P>





<P>&nbsp;</P>


<B><P ALIGN="CENTER">SIGNATURES</P>


<P ALIGN="CENTER"></P>


</B><P>Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>





<P>&#9;OXIS INTERNATIONAL, INC.</P>


<P>&#9;(Registrant)</P>





<P>&nbsp;</P>


<P>&nbsp;</P>


<P>Date:  October 19, 2004&#9;By:  <U>&#9;/s/  Gosse B. Bruinsma, MD&#9;</P>


</U><P>&#9;Gosse B. Bruinsma, MD</P><DIR>


<DIR>


<DIR>


<DIR>


<DIR>


<DIR>


<DIR>


<DIR>


<DIR>


<DIR>


<DIR>


<DIR>


<DIR>


<DIR>


<DIR>


<DIR>





<P>&#9;Acting Chief Financial Officer</P>


<FONT SIZE=2></DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</FONT></BODY>


</HTML>









</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
